VYNE
Vyne Therapeutics Inc
NASDAQ: VYNE · HEALTHCARE · BIOTECHNOLOGY
$0.67
+0.53% today
Updated 2026-05-06
Market cap
$21.39M
P/E ratio
—
P/S ratio
37.52x
EPS (TTM)
$-0.63
Dividend yield
—
52W range
$0 – $2
Volume
0.2M
Vyne Therapeutics Inc (VYNE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-4.18M | $-2.29M | $-28.25M | $-52.73M | $-65.10M | $-137.08M | $-56.37M | $-29.20M | $-25.34M | $-33.97M | $-33.12M |
| Capital expenditures | $0.00 | $31000.00 | $27000.00 | $140000.00 | $11000.00 | $113000.00 | $0.00 | $0.00 | $0.00 | $117000.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $65000.00 | $573000.00 | $1.45M | $3.64M | $6.70M | $18.10M | $8.08M | $4.30M | $3.31M | $3.30M | $2.31M |
| Free cash flow | $-4.18M | $-2.32M | $-28.27M | $-52.87M | $-65.11M | $-137.19M | $-56.37M | $-29.20M | $-25.34M | $-34.09M | $-33.12M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $33.87M | — | $294000.00 | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |